Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome? Moser U. BMJ Case Rep 2021;14.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Moser U. Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome? BMJ Case Rep 2021;14.
PMID: 34230048